Pivotal Therapeutics announces Notice of Allowance for U.S. Patent on its unique 6:1 EPA:DHA Formulation

January 29, 2014

WOODBRIDGE, ON, Jan. 29, 2014 /PRNewswire/ – Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies,
announced that it received a Notice of Allowance for U.S. Application
Serial Number US2012/025014 from the United States Patent and Trademark
Office (USPTO). The patent titled “Formulations Comprising Omega-3
Fatty Acids and Anti-Obesity Agent for the Reduction of Body Weight in
Cardiovascular Disease Patients (CVD) and Diabetics” covers Pivotal’s
unique formulation in conjunction with anti-obesity agents for the
reduction of body weight in CVD patients and diabetics. This notice
constitutes allowance of the patent and impending issuance.

“This Notice of Allowance is an important step in the process of
broadening our intellectual property portfolio, further validates our
unique 6:1 EPA:DHA formulation and when used in combination with
anti-obesity drugs may play a positive role in obesity,” said Dr.
George Jackowski, Chairman and Chief Scientific Officer. “Obesity and
diabetes are large markets, and this allowed patent may open the doors
to potential partnerships with pharmaceutical companies that are
currently working on treatments in these areas,” added Dr. Jackowski.

About Pivotal Therapeutics Inc.

Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CNSX: PVO)
specialty pharmaceutical company with a focus on cardiovascular disease
and overall health. Pivotal Therapeutics’ lead product VASCAZEN(®) is a prescription only Medical Food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease through
elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular complications. OMAZEN(® )is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in
each capsule for the maintenance of good health. OMAZEN(®) is a patented product available for sale and distribution in Canada.


VASCAZEN(®) is currently available in the U.S. as a prescription only Medical Food
specifically formulated for the dietary management of an Omega-3
deficiency in cardiovascular patients. VASCAZEN(®) is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid
formulation, protected by a series of both U.S. and foreign patents.

VASCAZEN(®) has been clinically shown to correct an Omega-3 deficiency within eight
weeks of treatment with positive concomitant effects on the lipid
profiles, mainly a 48% reduction of triglycerides and an increase of
HDL without negative impact on the LDL-C lipid profile. VASCAZEN(®)‘s results were achieved with a dose of 3 grams of EPA and DHA per day
of a prescription grade, high purity Omega-3.

Disclosure Notice

The information contained in this document is as of January 29, 2014.
This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal’s actual results
to differ materially from those projected in such forward-looking
statements. These statements can be identified by the use of words such
as “will”, “anticipate”, “estimate”, “expect”, “project”, “forecast”,
“intend”, “plan”, “believe”, “project”, “potential”, and similar
expressions with any discussion of future operating or financial
performance or events. In particular, factors that could cause actual
results to differ materially from those in forward looking statements
include the following: Pivotal’s inability to obtain additional
financing on acceptable terms; growth in costs and expenses; inability
to compete with others who provide comparable products; risk that the
Company’s products will not gain widespread market acceptance; risks
relating to the Company’s ability to maintain its CSNX listing.
Forward-looking statements speak only as of the date made and are not
guarantees of future performance. The Company undertakes no obligation
to publicly update or revise any forward-looking statements contained
in this document as a result of new information or future events or
developments. CNSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this information.

SOURCE Pivotal Therapeutics Inc.

Source: PR Newswire

comments powered by Disqus